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Abstract
Background: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen causing
female genital tract infection throughout the world. Reinfection with the same serovar, as well as multiple
infections with different serovars, occurs in humans. Using a murine model of female C. trachomatis genital
tract infection, we determined if homotypic and/or heterotypic protection against reinfection was induced
following infection with human oculogenital strains of C. trachomatis belonging to two serovars (D and H)
that have been shown to vary significantly in the course of infection in the murine model.
Methods: Groups of outbred CF-1 mice were reinfected intravaginally with a strain of either serovar D
or H, two months after initial infection with these strains. Cellular immune and serologic status, both
quantitative and qualitative, was assessed following initial infection, and the course of infection was
monitored by culturing vaginal samples collected every 2–7 days following reinfection.
Results: Serovar D was both more virulent (longer duration of infection) and immunogenic (higher level
of circulating and vaginal IgG and higher incidence of IgA in vaginal secretions) in the mouse genital tract.
Although both serovars induced cross-reacting antibodies during the course of primary infection, prior
infection with serovar H resulted in only a slight reduction in the median duration of infection against
homotypic reinfection (p ~ 0.10), while prior infection with serovar D resulted in significant reduction in
the median duration of infection against both homotypic (p < 0.01) and heterotypic reinfection (p < 0.01)
when compared to primary infection in age and conditions matched controls.
Conclusion: Serovar D infection resulted in significant homotypic and heterotypic protection against
reinfection, while primary infection with serovar H resulted in only slight homotypic protection. In addition
to being the first demonstration of acquired heterotypic immunity between human oculogenital serovars,
the differences in the level and extent of this immunity could in part explain the stable difference in serovar
prevalence among human isolates.
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Chlamydia trachomatis is the most common bacterial path-
ogen associated with sexually transmitted genital tract
infections both in the United States [1] and worldwide
[2]. It is generally accepted that most female genital tract
infections with C. trachomatis are both asymptomatic and
without severe sequelae [3]; and, that despite improved
screening programs and the availability of highly effective
antibiotics [4-6], there has been a significant increase in
the incidence of C. trachomatis genital tract infection
within the last half decade [2,7]. Although epidemiologic
studies suggest that prior infection with C. trachomatis
confers some short term protection against reinfection
[8,9], the exact nature of this acquired immunity remains
undetermined as do issues relating to the serovar specifi-
city and possible involvement of this immunity in the
more severe sequelae associated with multiple and/or
chronic infection [10-12].
It has been advanced that serovar specific immune
responses, particularly those made to the major outer
membrane protein (MOMP), contribute to protection,
whereas responses to broadly shared antigens, particularly
those induced by chlamydial heat shock protein 60
(Hsp60), are associated with the immunopathologic
injury that contributes to ectopic pregnancy and tubal
infertility [13-19]. There is also increasing evidence from
both human epidemiologic studies and animal model
experiments to support the hypothesis that a protective
immune response to reinfection is a complex, site of infec-
tion variable interaction between C. trachomatis and spe-
cific Th1 dominant cellular responses and interferon-
gamma mediated Th1 augmenting humoral responses
[20,21].
In attempts to understand the salient features and specific
components of this interplay, a great deal of work has
been performed using slightly modified versions of a
murine model of female genital tract infection first
described by Tuffrey and Taylor-Robinson [22]. In our
laboratory, we routinely use strains belonging to the
human oculogenital biovar of C. trachomatis and have pre-
viously reported significant differences in the course of
infection among strains belonging to 7 oculogenital sero-
vars, which loosely correlated with the prevalence of the
serovars among human clinical isolates, especially for the
most and least prevalent serovars, i.e. D and E versus H
and I [23].
The purpose of the present study was to expand on these
observations by assessing the degree of homotypic and
heterotypic protection against reinfection that follows res-
olution of infection with human isolates of C. trachomatis.
Two strains were selected from the previously studied col-
lection of strains: the strain of serovar D which was shown
to establish the longest duration of infection (median
duration of 38 days) and greatest humoral response; and
the serovar H strain which had the shortest duration
(median duration of 7 days) and lowest humoral
response. In addition, lower genital tract infection with
serovar D was shown to both ascend into the uterine
horns with a greater frequency than serovar H, as well as
shed more infectious units during the acute phase of
infection [23]. In a separate study we demonstrated a link
between certain in vitro growth characteristics and differ-
ences in the level of cytotoxic activity associated with ele-
mentary bodies between these strains [24]. Thus, strain
selection was made with the intention of reflecting the
greatest diversity observed among the strains studied in
the murine model, as well as to represent serovars that
have significantly different prevalence rates among
human isolates in the hope that the results of the study
would provide some insight into the possible causes of
these differences. Duration of genital tract infection was
used to determine the extent of protection, and humoral
and cellular immune response data were evaluated to
identify factors that associated with any observed protec-
tion.
Methods
Animals
Outbred CF-1 female mice (Charles River Labs) were pur-
chased at 7 weeks of age and were allowed to acclimate for
one week prior to use. All experiments were conducted in
a BL-2 containment facility in compliance with animal
care regulations and under protocols approved by the
institutional research animal care committee.
Bacteria and culture technique
Mycoplasma-free and pure PCR-typed strains of serovar D
and H [23,24] were propagated, purified, titrated, and iso-
lated in cycloheximide treated McCoy cell monolayers
using standard techniques. Separate vials of the same -
70°C stored stocks were used for both infections.
Murine model
Progesterone, in the form of medroxyprogesterone acetate
(Depo-Provera, Upjohn), was given subcutaneously (sc)
in 2.5 mg doses, 10 and 3 days prior to infection [22,23].
Prior to infection, vaginal specimens were obtained for
culture and cytology, and 2 hours later mice were inocu-
lated intravaginally by direct instillation of 25 µl of
sucrose phosphate buffered transport medium (SP) con-
taining 1–3 × 107 inclusion forming units (ifu).
Sample collection
The presence of Chlamydia in the lower genital tract was
determined by swabbing the vaginal vault and ectocervix
with a calcium alginate swab, which was cultured for the
organism. Plasma and vaginal secretions were obtainedPage 2 of 9
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incision, diluted 1:10 in PBS, and the plasma (P) was sep-
arated by centrifugation. Vaginal secretions (VS) were col-
lected over a two-hour period by absorption into a piece
of surgical sponge, and eluted into 400 µl of PBS. All sam-
ples were frozen at -20°C until tested.
Serological analyses
Anti-chlamydial IgG and IgA titers in blood and vaginal
secretions were determined by indirect solid phase
enzyme immunoassay (EIA) using SDS solubilized Ct ele-
mentary bodies as antigen. Western immunoblot analysis
were performed on a similar antigen preparation which
had been SDS-PAGE separated and transferred to nitrocel-
lulose paper. After incubation with sample (P at a final
dilution1:200; VS at a final dilution of 1:20), reactive
bands were visualized with standard EIA reagents.
Spleen cell analysis
Cellular immune responses were determined using a
standard assay for 3H-thymidine (3H-Td) incorporation.
Specific responses were measured using formalin pre-
served elementary bodies (EB) at a ratio of 100 EB:1
spleen cell, and non-specific responses measured using
concavalin A (Con A) at 2 µg/ml, phytohemagglutinin
(PHA) at 5 µg/ml, and lipopolysaccharide (LPS) at 100
µg/ml. Single-cell suspensions were prepared by gently
pressing the spleen through a nylon sieve. Debris was
allowed to settle for 2 min, and the supernatant contain-
ing single cells was spun down at 500 × g for 10 minutes.
Erythrocytes were lysed with NH4Cl solution and cells
were washed three times with RPMI 1640 medium con-
taining 10% fetal bovine serum and plated in triplicate, in
96-well plates at a concentration of 5 × 105 cells per well.
Proliferative responses were measured by uptake of 1 µCi
of 3H-thymidine (3HTd) per well for the last 24 hours of a
72 hour incubation period. As a measure of response, a
stimulation index (SI) was calculated (SI = 3H-Td incorpo-
ration with stimulation/3HTd incorporation without
stimulation).
Statistical evaluation
Duration of infection data were analyzed by the Wilcoxon
Rank Sum Test; meaned data by F-Test; and frequency
data by Chi Square.
Results
Homotypic and heterotypic protection against reinfection
Consistent with our previous report [23], intravaginal
inoculation with the serovar D strain resulted in a longer
duration of infection in previously uninfected mice com-
pared with the serovar H strain (22.5 days versus 15.5
days, p = 0.05) (Table 1). Analysis of the effect of prior C.
trachomatis genital tract infection on the duration of infec-
tion following homotypic and heterotypic reinfection
showed that infection with serovar H resulted in only
slight homotypic protection (15.5 days versus 10 days
duration of infection: p = 0.1), while serovar D infection
resulted in significant homotypic (22.5 days versus 12
days duration of infection: p < 0.01) and heterotypic pro-
tection (15.5 days versus 5 days duration of infection: p <
0.01) against reinfection (Table 1).
Humoral immune responses
Quantitative
As in our previous study [23], genital tact infection with
serovar D resulted in a significantly greater quantitative
anti-chlamydial humoral response compared to the
response to serovar H infection (Table 2). Serovar D
induced significantly higher plasma (p < 0.05) and vagi-
nal (p < 0.05) IgG levels as compared to serovar H.
Although no quantitative differences between the IgA
responses following infection with either serovar D and H
were observed in the vaginal secretions of animals with
detectable levels of antibody, a significant difference was
observed in the frequency of IgA positive vaginal secre-
Table 1: Acquired Homotypic and Heterotypic Immunity Against Oculogenital Chlamydia trachomatis Serovars Following Female 
Genital Tract Infection in Mice
Infection Serovar Number 
of 
Animals
Number of Animals Culture Positive on Reinfection Day Median 
Duration 
of 
Infection
Wilcoxon 
Rank Sum 
p Value
Initial1 Reinfection 2 4 6 8 10 14 17 21 24 28 31 35 38 42 45 48 52 55
D H 12 12 5 3 2 5 2 1 0 0 0 0 0 0 0 0 0 0 0 5 <0.01
H H 12 12 11 8 8 10 3 1 2 0 0 0 0 0 0 0 0 0 0 10 ~0.10
None H 12 12 12 12 12 11 6 5 2 2 1 0 0 1 0 0 0 0 0 15.5 --
D D 12 12 9 7 9 7 5 4 2 2 1 0 0 0 0 0 0 0 0 12 <0.01
H D 12 12 12 12 12 11 6 10 7 7 4 1 2 1 0 0 0 0 0 24 NS
None D 12 12 12 12 12 11 7 5 6 4 4 2 1 1 2 0 0 0 0 22.5 --
1Median duration of infections during the primary infection phase of this study were 10 days with serovar H and 33 days with serovar D.Page 3 of 9
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fection (11/24 for H vs 21/24 for D, p < 0.01, data not
shown). In all cases, similar homologous and heterolo-
gous antibody titers were detected against both antigen
preparations used in the assay.
Qualitative
Tables 3 and 4 contain the Western immunoblot analysis
of plasma and vaginal secretions from representative ani-
mals following resolution of initial infection and immedi-
ately prior to reinfection with serovar H (Table 3) or with
serovar D (Table 4). Consistent with the quantitative find-
ings, plasma and vaginal secretions from serovar D
infected mice contained antibodies to a greater array of
antigens than specimens from serovar H infected mice;
and although often more intense when homologous,
plasma from mice infected with either serovar gave similar
immunoblot patterns against both antigen preparations,
thus demonstrating the induction of a high level of cross-
reacting IgG during infection.
With the exception of the link between quantitative
humoral response and protection, statistical analysis of
the serologic and duration of infection data did not detect
a humoral factor(s) that correlated with the shorter dura-
tion of infection observed following reinfection.
Splenic lymphocyte responses
Table 5 summarizes the chlamydia-specific and mitogen
non-specific splenic lymphocyte responses obtained from
groups of four animals 55 days following genital tract
inoculation with either serovar H or D. Mean responses to
PHA and both elementary body preparations were greater
following infection with either serovar when compared to
non-infected controls (p 0.05); while responses to both
Con-A and LPS were not different from controls. No asso-
ciation could be found between a particular pattern or
magnitude of cellular responses and an individual ani-
mals duration of infection.
Discussion
Using a murine model of C. trachomatis female genital
tract infection, we have demonstrated that homotypic
immunity against reinfection was induced following ini-
tial infection with either serovar D or H, but that a more
significant level of protection was observed following
infection with serovar D. However, heterotypic protection
against reinfection was strain dependant and was seen
only when the initial infection was with the more virulent
and immunogenic strain of serovar D. These results are
the first demonstration of heterotypic immunity between
two oculogenital serovars following female genital tract
infection in the mouse model, as well as being the first
Table 2: Serologic Analysis of Plasma and Vaginal Secretions Following Infection and Immediately Prior to Reinfection with Chlamydia 
trachomatis Serovars D and H
Plasma and Vaginal Secretion Titers (Log 2) (p Value)
Infection Serovar Number of 
Animals
Plasma IgG VS IgG VS IgA1
Primary Secondary H D H D H D
D H 12 13.0 13.6 8.3 8.7 7.2 8.3
(<0.05) (<0.05) (NS)
H H 12 11.0 11.2 5.3 6.1 6.7 6.8
None H 12 <6 <6 <2 <2 <2 <2
D D 12 12.5 13.1 7.8 8.3 7.3 7.6
(<0.05) (<0.05) (NS)
H D 12 11.4 11.4 5.3 5.5 6.0 6.4
None D 12 <6 <6 <2 <2 <2 <2
1Values listed are the mean titers of IgA positive animals only.
Table 5: Splenic Lymphocyte Responses 55 Days After Primary Infection with Serovars H and D
Mean Stimulation Index ± 1 SEM
EB Serovar Standard Mitogens
Group H D Con-A PHA LPS
Control 13.0 ± 1.7 15.9 ± 1.8 79.5 ± 12.0 6.2 ± 1.8 58.4 ± 5.3
H 19.2 ± 3.1* 23.4 ± 4.1* 96.2 ± 15.6 11.3 ± 6.4* 58.7 ± 15.8
D 19 ± 1.5* 21.7 ± 1.7* 78.8 ± 6.8 11.9 ± 6.4* 51.1 ± 6.3
*Significantly different from Control mean at p 0.05Page 4 of 9
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Table 3: Serological Analysis of Plasma and Vaginal Secretions from Representative Animals Following Primary Infection with Either 
Chlamydia trachomatis Serovar H or D and Immediately Prior to Infection with Serovar H
H Primary Infection D Primary Infection
Animal J1 H3 J3 L1 H4 J2 R1 X1 X2 R4 T2 Y4
Infection Duration (Days)
Primary 24 24 8 24 6 24 38 42 24 42 28 42
Secondary 2 4 10 10 21 21 2 2 4 6 14 17
Plasma and Vaginal Secretion Titers (Log 2) and IgG Immunoblot Reactions Against serovar H and D
H D H D H D H D H D H D H D H D H D H D H D H D
P IgG 14 13 13 13 7 8 13 13 7 8 13 13 12 13 13 14 13 13 14 14 13 13 12 13
V IgG 8 8 8 8 2 3 9 9 <2 <2 8 9 7 8 8 7 8 9 8 8 8 8 8 8
V IgA 9 8 8 8 <2 <2 8 8 <2 <2 4 4 5 7 8 9 7 8 7 8 8 9 8 9
MW (kD) P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V
190 - - - - - - -
140
120 · - · -
115
110 · ·
108
106 • • • •
102
100 - ·
96
92 · - • ·
90
78 · -
72
66 · - · - • ·
64
62 · - · · • · · • • - • · · · • · • · • · · - · · • · • ·
61.5
60 ● · • • • · • • · - · - • • ● • • • • • • • • • • ● • • ● • • • ● • • •
58 · -
56 · -
50 · - · - · -
46.5 • · ● • · - • · · - ● · · - ● • • • • • • · • • • • • · · - ● ●
40
38
36 · - · - · -
33
29 · - · - · - • • • • · · • •
26
22.5 • -
19.5
15.5 · · · ·
- = No reaction
Plasma = P
· = Barely visible
Vaginal secretions = V
• = Weak
●  = Strong
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Table 4: Serological Analysis of Plasma and Vaginal Secretions from Representative Animals Following Primary Infection with Either 
Chlamydia trachomatis Serovar H or D and Immediately Prior to Infection with Serovar D
H Primary Infection D Primary Infection
Animal I1 G3 K2 G2 K3 I4 Z1 S4 Q4 Z2 Q2 S1
Infection Duration (Days)
Primary 6 10 6 31 14 6 45 21 14 45 52 10
Secondary 10 17 24 28 35 38 2 4 10 14 24 28
Plasma and Vaginal Secretion Titers (Log 2) and IgG Immunoblot Reactions Against serovar H and D
H D H D H D H D H D H D H D H D H D H D H D H D
P IgG 11 11 13 13 11 11 12 12 9 9 13 11 14 14 12 13 11 11 13 14 14 14 11 11
V IgG 5 5 7 6 2 4 6 7 4 4 5 5 11 11 7 7 7 8 9 10 9 9 4 5
V IgA <2 <2 <2 <2 <2 <2 7 8 <2 <2 <2 2 3 5 <2 <2 4 6 8 9 10 9 <2 <2
MW (kD) P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V P V
190 - - - - - - -
140
120 · -
115
110
108
106 · - · -
102
100
96
92 - ·
90
78 · -
72
66 · -
64
62 ● · • - • · • • · · • · · · · · · - ● · ● · ● ● ● ●
61.5
60 ● • ● • · - · - • · • · ● • • • • · • • · - · · • · • - • • • • · · • ·
58
56
50
46.5 · - · - ● • • · • · • · • · · - ● · • · · - ● • · - • • • · • · · - ● • · - • ·
40
38 - ·
36 • · • • · - · -
33
29 · - · - - · • · • • · - · - · · • ·
26
22.5 · - · -
19.5 · - · · · -
15.5 · · · ·
- = No reaction
Plasma = P
· = Barely visible
Vaginal secretions = V
• = Weak
●  = Strong
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ent restriction on the process. The findings are consistent
with other studies that have observed heterotypic immu-
nity in the context of MoPn and serovar E. Also consistent
with prior reports is the correlation between the level of
protection observed and the virulence of the strains used
to infect the mouse genital tract, with the more virulent
MoPn inducing a more solid level of heterotypic immu-
nity against serovar E than was observed in the reverse sit-
uation [25,26]. Finally, the observed differences in
heterotypic and homotypic responses between serovars D
and H could explain in part the relatively stable differ-
ences in the frequency of these two serovars among
human isolates from different geographic locations [27-
33], i.e. a prior infection with a more virulent/immuno-
genic serovar would confer a greater degree of protection
against infection with a less virulent/immunogenic sero-
var, thus reducing the incidence of the latter by reducing
the efficiency of serial transmission.
Consistent with human epidemiologic data [8,9], the pro-
tection observed in this model against reinfection with
oculogenital serovars of C. trachomatis was not complete,
but rather acted in a way that reduced the duration of
infection and level of bacterial shedding (data not shown)
during infection. With the notable exception that serovar
H infection resulted in a lesser quantitative and qualita-
tive humoral response, a thorough analysis of the individ-
ual and collective data was unable to identify any specific
element(s) that correlated with protection. This finding is
consistent with a report in which a similarly extensive
analysis of cellular and humoral responses was performed
in a comparison of the acquired immunity induced by
infection with MoPn and serovar E [25]. Although not
proof, this does support the current working hypothesis
that acquired immunity to C. trachomatis female genital
tract infection is a complex and integrated phenomena
that relies on both Th1 and Th2 type responses made dur-
ing the course of infection, which in turn enhance innate
immune responses upon reinfection [20]. This complex-
ity, which likely arises out of the ever changing physio-
logic and immunologic milieu within and between
anatomically distinct but connected regions of the female
genital tract, may account for the difficulty identifying
specific components of what may be a flexible pattern of
responses that lead to a given individual's level of protec-
tion against or risk of severe upper genital tract pathology
[21].
Women with recurrent C. trachomatis infection are at
increased risk of reproductive sequelae, including pelvic
inflammatory disease, ectopic pregnancy and tubal infer-
tility [10-12], which have been linked to both cellular and
humoral immune responses induced during infection
[13-19]. How the nature and level of homotypic and/or
extent of heterotypic immunity in the murine model
extrapolate to the risk of upper genital tract pathology and
infertility was not assessed in this study, and is an area of
investigation that has yet to be systematically addressed.
Most of the experimental data relating to the severe seque-
lae associated with C. trachomatis female genital tract
infection has been obtained in studies using C. muri-
darum, MoPn [34,35]. As a result, it has not been possible
to clearly assess the immunologic features that are
thought to contribute to severe sequelae within the
human female genital tract, because the damage that
occurs within the murine genital tract following infection
with MoPn is a consequence of acute and not chronic
infectious processes and/or recurrent infection [36,37].
Typically in the mouse and in most women, human ocu-
logenital serovars are limited in their ability to ascend
with any major pathologic consequence from the initial
site of infection within the lower genital tract. However,
infection of female C3H/HeN with a strain of serovar E
has been shown to ascend and cause infertility without
gross pathology at a low incidence following a single
infection and with increased incidence upon reinfection
[26]. Of particular interest is that none of these mice
developed hydrosalpinx, which is the hallmark of upper
tract infection with MoPn, indicating a possible alterna-
tive mechanism for the induction of infertility, one differ-
ent from the tubal dilation, scarring and associated
hydosalpinx that occurs as a sequelae to MoPn infection.
Although no specific immunologic mechanism was iden-
tified as contributing to the development of infertility, it
was noted that the C3H/HeN mouse is an Hsp60
responding strain and that Hsp60 responding strains of
mice are more susceptible to MoPn induced infertility
while non-responders can be infected but do not experi-
ence severe upper tract pathology. It will be worthwhile to
determine if the two C. trachomatis strains used in the
present study show a similar relationship to each other in
C3H/HeN mice and whether homotypic and/or hetero-
typic elements of immunity play a role in the progression
of events that lead to severe upper tract pathology, which
is essentially the reason why C. trachomatis genital tract
infections are significant and why intervention and pre-
vention strategies are needed.
Conclusion
In conclusion, we demonstrate in the first study compar-
ing phenotypically different strains representing two
human oculogenital serovars that both the level of homo-
typic protection against reinfection and the ability to con-
fer heterotypic protection correlated with the virulence/
immunogenicity of the strain. Extrapolating the results to
human epidemiologic data could explain in part the rela-
tively stable differences in the frequency between the most
and least prevalent serovars based on a serovars ability to
induce or not induce heterotypic immunity. Although noPage 7 of 9
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BMC Infectious Diseases 2005, 5:105 http://www.biomedcentral.com/1471-2334/5/105specific cellular or humoral factor(s) could be identified
that associated with the observed protection, it is clear
that heterotypic immunity can be induced and that the
systematic study of human oculogenital serovars in the
mouse model of female genital tract infection could pro-
vide information that leads to an understanding of what
distinguishes a protective from an immunopathic
response to infection.
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